# TScan Therapeutics (TCRX) — Earnings

TCRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tcrx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.28 |
| EPS estimate | −$0.33 |
| EPS surprise | +14.40% |
| Revenue surprise | +135.71% |
| Revenue | $3.1M |
| Revenue estimate | $1.3M |
| Reported | Aug 12, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1783328/000095017025106919/tcrx-20250630.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 12, 2025 | −$0.33 | −$0.28 | 14.40% | $1.3M | $3.1M |
| Q1 2025 | May 6, 2025 | −$0.29 | −$0.26 | 10.87% | $1.1M | $2.2M |
| Q4 2024 | Mar 5, 2025 | −$0.32 | −$0.30 | 5.90% | $1.5M | $665,000.00 |
| Q3 2024 | Nov 12, 2024 | −$0.32 | −$0.25 | 20.74% | $1.2M | $1.0M |
| Q2 2024 | Aug 12, 2024 | −$0.28 | −$0.28 | 1.03% | $1.8M | $536,000.00 |
| Q1 2024 | May 13, 2024 | −$0.26 | −$0.32 | -23.46% | $4.0M | $600,000.00 |
| Q4 2023 | Mar 6, 2024 | −$0.29 | −$0.21 | 27.39% | $3.5M | $7.2M |
| Q3 2023 | Nov 9, 2023 | −$0.45 | −$0.24 | 46.97% | $4.5M | $3.9M |
| Q2 2023 | Aug 10, 2023 | −$0.77 | −$0.51 | 33.33% | $4.4M | $3.1M |
| Q1 2023 | May 10, 2023 | −$0.69 | −$0.93 | -34.30% | $4.9M | $6.8M |
| Q4 2022 | Mar 8, 2023 | −$0.72 | −$0.78 | -7.73% | $4.1M | $3.1M |
| Q3 2022 | Nov 9, 2022 | −$0.73 | −$0.67 | 7.71% | $3.9M | $3.4M |
| Q2 2022 | Aug 10, 2022 | −$0.74 | −$0.63 | 15.32% | $3.0M | $4.1M |
| Q1 2022 | May 9, 2022 | −$0.70 | −$0.67 | 4.29% | $2.8M | $3.0M |
| Q4 2021 | Mar 9, 2022 | −$0.70 | −$0.60 | 14.29% | $3.5M | $2.9M |
| Q3 2021 | Nov 10, 2021 | −$0.61 | −$0.80 | -32.23% | $3.5M | $2.4M |
| Q2 2021 | Aug 19, 2021 | −$0.65 | −$7.69 | -1092.25% | $3.4M | $2.8M |

## Frequently Asked Questions

### When did TScan Therapeutics (TCRX) last report earnings?

TScan Therapeutics last reported on Aug 12, 2025, covering fiscal Q2 2025.

### Did TCRX beat earnings estimates?

Yes. TScan Therapeutics reported EPS of −$0.28 for Q2 2025 against a −$0.33 estimate — a 14.40% beat.

### How much revenue did TCRX report last quarter?

TScan Therapeutics reported $3.1M in revenue for Q2 2025, against a consensus estimate of $1.3M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).